Xiao Tong

Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors.

Robert Chase, Sony Agrawal, X. Tong, 2008, Biochemical pharmacology.

Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.

Weiying Yang, Frank Bennett, Jesse Wong, 2010, ACS medicinal chemistry letters.

Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.

Frank Bennett, X. Tong, A. Arasappan, 2009, Journal of medicinal chemistry.

Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.

Zhuyan Guo, Frank Bennett, Sumei Ruan, 2009, Journal of medicinal chemistry.

The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.

Zhuyan Guo, Frank Bennett, X. Tong, 2010, Bioorganic & medicinal chemistry letters.

Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.

Weiying Yang, Frank Bennett, X. Tong, 2009, Journal of medicinal chemistry.

Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.

Andrea Hart, Robert Chase, Sony Agrawal, 2009, Journal of medicinal chemistry.